|
1
|
Ilic M and Ilic I: Epidemiology of
pancreatic cancer. World J Gastroenterol. 22:9694–9705. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ma J, Siegel R and Jemal A: Pancreatic
cancer death rates by race among US men and women, 1970–2009. J
Natl Cancer Inst. 105:1694–1700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Limani P, Samaras P, Lesurtel M, Graf R,
DeOliveira ML, Petrowsky H and Clavien PA: Pancreatic cancer- a
curable disease. Praxis (Bern 1994). 104:453–460. 2015.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mohammed S, Van Buren G II and Fisher WE:
Pancreatic cancer: Advances in treatment. World J Gastroenterol.
20:9354–9360. 2014.PubMed/NCBI
|
|
7
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beuran M, Negoi I, Paun S, Ion AD, Bleotu
C, Negoi RI and Hostiuc S: The epithelial to mesenchymal transition
in pancreatic cancer: A systematic review. Pancreatology.
15:217–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bergmann JH and Spector DL: Long
non-coding RNAs: Modulators of nuclear structure and function. Curr
Opin Cell Biol. 26:10–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cui M, You L, Ren X, Zhao W, Liao Q and
Zhao Y: Long non-coding RNA PVT1 and cancer. Biochem Biophys Res
Commun. 471:10–14. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graham M and Adams JM: Chromosome 8
breakpoint far 3′ of the c-myc oncogene in a Burkitt's lymphoma 2;8
variant translocation is equivalent to the murine pvt-1 locus. EMBO
J. 5:2845–2851. 1986.PubMed/NCBI
|
|
12
|
Tseng YY, Moriarity BS, Gong W, Akiyama R,
Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell
TC, et al: PVT1 dependence in cancer with MYC copy-number
increase. Nature. 512:82–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guan Y, Kuo WL, Stilwell JL, Takano H,
Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, et al:
Amplification of PVT1 contributes to the pathophysiology of ovarian
and breast cancer. Clin Cancer Res. 13:5745–5755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Z, Zhu Z, Zhang B, Li W, Li X, Wu X,
Wang L, Fu L, Fu L and Dong JT: Frequent mutation of rs13281615 and
its association with PVT1 expression and cell proliferation
in breast cancer. J Genet Genomics. 41:187–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meyer KB, Maia AT, O'Reilly M, Ghoussaini
M, Prathalingam R, Porter-Gill P, Ambs S, Prokunina-Olsson L,
Carroll J and Ponder BA: A functional variant at a prostate cancer
predisposition locus at 8q24 is associated with PVT1
expression. PLoS Genet. 7:e10021652011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS
and Feng XJ: Increased expression of the lncRNA PVT1 promotes
tumorigenesis in non-small cell lung cancer. Int J Clin Exp Pathol.
7:6929–6935. 2014.PubMed/NCBI
|
|
17
|
Ding J, Li D, Gong M, Wang J, Huang X, Wu
T and Wang C: Expression and clinical significance of the long
non-coding RNA PVT1 in human gastric cancer. OncoTargets
Ther. 7:1625–1630. 2014. View Article : Google Scholar
|
|
18
|
You L, Chang D, Du HZ and Zhao YP:
Genome-wide screen identifies PVT1 as a regulator of Gemcitabine
sensitivity in human pancreatic cancer cells. Biochem Biophys Res
Commun. 407:1–6. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang C, Yu W, Wang Q, Cui H, Wang Y,
Zhang L, Han F and Huang T: Increased expression of the lncRNA PVT1
is associated with poor prognosis in pancreatic cancer patients.
Minerva Med. 106:143–149. 2015.PubMed/NCBI
|
|
20
|
Xu T, Jing C, Shi Y, Miao R, Peng L, Kong
S, Ma Y and Li L: microRNA-20a enhances the
epithelial-to-mesenchymal transition of colorectal cancer cells by
modulating matrix metalloproteinases. Exp Ther Med. 10:683–688.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang S, Zhang G and Liu J: Long noncoding
RNA PVT1 promotes cervical cancer progression through
epigenetically silencing miR-200b. APMIS. 124:649–658. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kong R, Zhang EB, Yin DD, You LH, Xu TP,
Chen WM, Xia R, Wan L, Sun M, Wang ZX, et al: Long noncoding RNA
PVT1 indicates a poor prognosis of gastric cancer and
promotes cell proliferation through epigenetically regulating p15
and p16. Mol Cancer. 14:822015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bogachek MV, De Andrade JP and Weigel RJ:
Regulation of epithelial-mesenchymal transition through SUMOylation
of transcription factors. Cancer Res. 75:11–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Katsuno Y, Lamouille S and Derynck R:
TGF-β signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heldin CH, Miyazono K and ten Dijke P:
TGF-beta signalling from cell membrane to nucleus through SMAD
proteins. Nature. 390:465–471. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Y, Sheng J, Dai D, Liu T and Qi F:
Smad4 acts as tumor suppressor by antagonizing lymphangiogenesis in
colorectal cancer. Pathol Res Pract. 211:286–292. 2015. View Article : Google Scholar : PubMed/NCBI
|
